Index

Page numbers in italic refer to figures and bold refer to tables.

abdominal wall, see also hernias
radiotherapy, 216
aberrant differentiation, carcinomas with, 8–9
Abraxane, 103, 312
accessory obturator vein, 136
access to healthcare see barriers to healthcare
Accountable Care Organizations, 399
ACE‐27 (Adult Comorbidity Evaluation‐27), 114
acetaminophen, 132
acetylation, histones, 316
Action on Bladder Cancer (UK), 403–404
activities of daily living, recovery prediction, 116
adalimumab, BCG therapy and, 82–83
adenocarcinoma, 10–11, 213–215, see also specific types
urachal carcinoma vs, 12
adjuvant chemotherapy, 295–303
to bladder‐sparing therapy, 226
to chemoradiation, 225
cisplatin‐based, 289
disadvantages, 299
neoadjuvant chemotherapy vs, 285–286
partial cystectomy, 218
after surgical consolidation, 192
transurethral resection, 58, 59–60, 208
HGT1 bladder cancer, 92
single‐dose, 59, 66–68
adjuvant radiotherapy, 193
partial cystectomy, 218
Adult Comorbidity Evaluation‐27, 114
advocacy (cancer patient advocacy), 402–408
Affordable Care Act, 398–399
African Americans, bladder carcinoma mortality, 368–369
AG chemotherapy (doxorubicin plus gemcitabine), 307–308
age
bladder‐sparing therapy, 223–224, 228
on compliance, 377
extended lymphadenectomy, 179–180
functional status and, 113
non‐continent urinary diversions, 258–259
orthotopic neobladders, 145–146, 236, 387
continence, 239–240
quality of life, 387
radical TURBT, 203–204, 205f, 206f
robot‐assisted radical cystectomy, 387
outcome studies, 157, 158, 172
age‐adjusted Charlson Comorbidity Index, 113
albumin, serum levels, 116, 117
albumin‐bound paclitaxel (Abraxane), 103, 312
algorithms, advanced carcinoma, 194–196
alkaline phosphatase, 130
alpha‐microglobulin, 266
alvimopan, 120, 131, 132
American Bladder Cancer Society, 404
American Cancer Society, 402
National Patient Navigation Leadership Summit, 371
Report to the Nation on Cancer in the Poor, 366
American College of Cardiology/AHA guidelines, 117–118
American Society of Anesthesiologists Score, 114
American Urological Association
on follow‐up, 375, 376
healthcare quality measures, 398
5‐aminolevulinic acid, 41, 71, 105
ammonia, 118
amplifications of genes, 330
ERBB2 gene, monoclonal antibody therapy, 315
anastomoses
Mainz pouch I, 249
Mainz pouch III, 253
strictures
non‐continent urinary diversions, 264–265
orthotopic neobladders, 240, 241
robot‐assisted radical cystectomy, 159–160
ureterointestinal, 255, 264–265
anatomy
blood supply and innervation, 128–129
extended lymphadenectomy, 145
female urethra, 146–147
lymphatic drainage, 177
androgen receptor, carcinogenesis and, 145
anesthesia, see also local anesthesia
obturated reflex, 54
radical cystectomy, evaluation for, 119–120
transurethral resection, 52

© 2015 John Wiley & Sons, Ltd. Published 2015 by John Wiley & Sons, Ltd.
angiogenesis
carcinoembryonic antigen-related cell adhesion molecule 1, 30
therapy inhibiting, 312–314, 354
anterior apical dissection (male), radical cystectomy, 138
anterior pelvic exenteration, 134, 145
Mainz pouch III, 253
techniques, 148–150
anthracyclines, 65, see also specific drugs
anti-angiogenic therapy, 312–314, 354
antibiotics
prophylaxis
radical cystectomy, 132
transurethral resection, 52
therapy, BCG infection, 83
antiemetics, 132
antimetabolites, 65
antimicrotubule agents, 65
antiplatelet therapy, 119
anti-refluxing techniques, ureter implantation, 253–255
anti-TNF drugs, BCG therapy and, 82–83
antituberculous therapy, BCG infection, 83
anxiety, 379, see also fear of recurrence
apraziquone, 65
appendix, submucosal tunneling, 246, 249, 250f
ARF protein, 335
ARID1A gene mutations, 335
arrhythmias, paclitaxel, 103
arthritis, BCG therapy, 82
ASA (American Society of Anesthesiologists) Score, 114
aspirin, 119
atypia, 6
atypia of uncertain significance, 4–5, 6
AURKA (Aurora kinase A), biomarker, 30
autonomic nerve fibers
continence and, 147, 148f
preservation, 149
AzaC (5-azacitidine), 357–358
bacille Calmette-Guérin see BCG therapy
bacteriuria, 264, see also pyelonephritis; urinary tract infections
barriers to healthcare, 367, 368, 369–370
cystoscopy, 379–380
basal cells, 344
basal subtype, 345
epithelial-to-mesenchymal transition in, 348
transcription factors in, 346–347
base excess, 256
BCG-intolerant urothelial carcinoma, 100
BCG-refractory urothelial carcinoma, 78, 94, 98, 100
docetaxel, 70, 102–103
gemcitabine, 70, 101–102
mitomycin-C vs, 102
treatment, 101–106
BCG-relapsing urothelial carcinoma, 100
BCG-resistant urothelial carcinoma, 100
BCG therapy, 65, 76–83, 84–85, 359
combination chemotherapy, 70
EMDA-MMC after, disease-free interval, 71
failure, 98–108
definition, 99
HGT1 bladder cancer, 93
non-surgical treatment, 22–23
on progression, 94, 98, 99, 100
HGT1 bladder cancer, 92, 93
interferon-alpha with, 23, 83–84
lenalidomide with, 358
photodynamic diagnosis cystoscopy after, 42
production shortage, 92
on progression, 22, 77, 79, 92
quality of life, 386
in sequential chemotherapy, 69
for T1 urothelial carcinoma, 22
failure, 100
Ta urothelial carcinoma, 20–21
toxicity, 79–83
transurethral resection with, 59
for urethral carcinoma, 188
BCL2, gene methylation, 30
BCL2L1 gene, HPV16 integration, 336
benign tumors, partial cystectomy, 215
bevacizumab, 311t, 354
GC chemotherapy with, 311t, 312–313
MVAC chemotherapy with, 290
BGJ-398 (FGFR inhibitor), 355
bilateral ureterostomy, 260
bimanual examination
preoperative preparation, 112
staging, 130
at transurethral resection, 53
biomarkers, 26–38
basal subtype of bladder carcinoma, 348
for bladder-sparing therapy, 229
for chemotherapy response, 274–276, 290, 308–309
FDA-approved, 27–33
genomics, 33, 301
HGT1 bladder cancer, 91
investigational, 29–33
risk stratification and, 20
survivin, 32, 322
biopsy
gene expression, 281
HGT1 bladder cancer, 90
follow-up, 91
prostate, 185
prostatic urethra, 90, 129
radical TURBT, 203
staging, 129
at transurethral resection, 54
bipolar cutting loop, 54
bisacodyl, 132
black patients, bladder carcinoma mortality, 368–369
Bladder Cancer Advocacy Network, 403
educational tools, 404
research collaborations, 406
Survivorship Working Group, 380
Bladder Cancer Basics for the Newly Diagnosed (BCAN), 404
Bladder Cancer Canada, 403, 406
Bladder Cancer Outcomes Study, 378–379
Bladder Cancer Task Force, National Cancer Institute, 406
Bladder Cancer Think Tank, 406
bladder function, bladder-sparing therapy, 227
bladder neck tumor, urethral cancer with, 186
bladder pedicles, radical cystectomy, 137–138
bladder-sparing therapy, 201, 212, see also specific procedures
multimodality, 218, see also trimodality bladder-sparing therapy
quality of life, 385
outcomes, 228
bladder tumor antigen tests (BTA tests), 27–28
BLCA-1 (biomarker), 30
BLCA-4 (biomarker), 30
bleaching see photobleaching
blockade, obturator nerve, 54
blood loss (EBL), robot-assisted radical cystectomy, 158, 173
blood supply, 128
female urethra, 146
body mass index, 116
robot-assisted radical cystectomy, outcome studies, 157, 158
bone marrow toxicity, 324
bone scintigraphy, 130
bortezomib, 311t, 316
bowel function return, see also ileus
robot-assisted radical cystectomy, 159
bowel preparation, 131, 132
continent cutaneous diversions, 245
non-continent urinary diversions, 259
breast cancer, research funding, 405
breast cancer susceptibility gene 1 (BRCA1), 274, 275t, 309
bropirimine, 105
BTA Stat test, 27
BTA Trak test, 27–28
bulge stem cells, 343
bullae, optical coherence tomography, 47
bundled payment initiatives, 398–399
C16orf74 (biomarker), 91
cabozantinib, 356
calcium-signal transducer 2 (biomarker), 33
camera port, partial cystectomy, 217
Canada, Bladder Cancer Canada, 403
Cancer Care for the Whole Patient (IOM), 380
Cancer Genome Atlas, The (TCGA), 301
cancer patient advocacy, 402–408
Cancer Program Standards 2012, 366
cancer-specific survival
radical cystectomy, 168
radical TURBT, 203, 204, 206f
cancer stem cells, 344–345
cancer survivorship care plans, 380, 390
candidate genes, 277
carbohydrate loading, 131, 132
carboplatin, 308, 311t, 322
bevacizumab with, 313
myelotoxicity, 324
in neoadjuvant chemotherapy, 289
trastuzumab with, 315–316
carcinoembryonic antigen-related cell adhesion molecule 1, 30
carcinoma in situ (CIS)
BCG-refractory, treatment, 101–106
BCG therapy, 78
flat urothelial, 5f, 6
HGT1 bladder cancer with, 93
photodynamic diagnosis cystoscopy, 21, 41
risk of cancer progression, 99
risk stratification, 21–22
carcinosarcoma, 14
cardiovascular disease, see also arrhythmias
immediate vs salvage cystectomy, 227
risk assessment, 117–118, 131
care pathways, 122–123, 131–132, 192
care plans (cancer survivorship care plans), 380, 390
catheterization
for anterior pelvic exenteration, 149
continent urinary diversions, 121–122, 146, 244–245
orthotopic neobladders, 236
quality of life, 386–387
catheters (subfascial), local anesthesia, 132
caveolin-1, 309
CCDN1 gene, 335
CD44, monoclonal antibodies, cancer stem cell staining, 344
CD44-negative tumors, 345
CD90 (cancer stem cell marker), 345
CDKN1A gene deletions, 335
CDKN2A gene deletions, 330, 331f, 332f, 335
CEACAM1 (biomarker), 30
CEACAM6 (cancer stem cell marker), 344
cell cycle gene mutations, 335
cellphone ownership, 381–382
Cellvizio (confocal laser endomicroscopy), 45–46
Centers for Medicare & Medicaid Services (CMS)
bundled payment initiatives, 398
Physician Quality Reporting System, 397
centers of excellence, 397
cetuximab, 311t, 316, 355, 356t
Charlson Comorbidity Index, age-adjusted, 113
Charlson Index Score, 113
chemoradiation, 222, 224–225, 286
non-muscle-invasive bladder cancer, 228–229
outcomes, 228
Index

chemotherapy, see also thermo-chemotherapy
adjuvant see adjuvant chemotherapy
advanced carcinoma, 191, 194, 195
intravenous, molecular targeted agents, 65–66
intravesical see intravesical chemotherapy
molecular biology, 273–283, 290, 301, see also biomarkers
neoadjuvant see neoadjuvant chemotherapy
before partial cystectomy, 213
at partial cystectomy, 216
with partial cystectomy, 218
poor risk patients, 320–321, 323–324
radiotherapy with, 221–232, 286
urachal carcinoma, 214–215
chromatin-modifying genes, 301, 330
chromatin regulatory gene mutations, 335–336
chromosomal rearrangements, 336–337
chromosomal regions, gene amplification, 330
circular smooth muscle, female urethra, 147
circumflex iliac vein, 136
CISCA chemotherapy, metastases, 304
cisplatin, single-agent chemotherapy, 288, 299, 304–305
cisplatin-based chemotherapy, see also MVAC chemotherapy
MCV chemotherapy, 226
metastases, 191–192, 304–306
molecular biology, 273–283
muscle-invasive bladder carcinoma, 191
neoadjuvant, 284–294
nephrotoxicity, 117
radiotherapy with, 224, 225
transurethral resection of bladder cancer, 209
unfitness for, 119, 321–322
CK5 (cancer stem cell marker), 345
CK14 (cancer stem cell marker), 345
CK20 (cancer stem cell marker), 345
damping, partial cystectomy, 215, 216f
deo-rectal technique, vaginal closure, 150
clear cell adenocarcinoma, 11
clinical trials
participation levels, 404–405
partnering by advocacy groups, 406–407
clinician-led urological collaboratives, 399
Clastridium difficile colitis, avoidance, 121
Clusters I–IV, mRNA expression subtypes, 337, 338f
coaexpression extrapolation (COXEN) approach, gene
eexpression models, 279–281, 309
colon
conduit urinary diversions, 245, 246–247, 262–263
contractions, 256
imaging, 245
non-continent urinary diversions, 260
pouches made from, 238, 246–247
Mainz pouch III, 253, 254f
at radical cystectomy, 135
stomas, 262–263
colonoscopy, 112
colorectal carcinoma, partial cystectomy, 215
combinations, intravesical chemotherapy, 69
combined-modality treatment see multimodality bladder-sparing therapy; trimodality bladder-sparing therapy
Commission on Cancer
accreditation requirements, 366, 367
on patient navigation, 366–367
common iliac arteries, at radical cystectomy, 136
common iliac veins, at radical cystectomy, 136
comorbidity, 387
assessment, 113–114
neoadjuvant chemotherapy and, 288
compliance, with follow-up, 376, 377, 379–380
computed tomography, 130, 376
conduit urinary diversions, 245, 260–262, see also ileal conduits
confocal laser endomicroscopy, 40f, 44–46, 48
congestive heart failure, 118
Connaught strain, BCG, 92
consolidation (surgical), 191–193, 194, 196
continence, female urethra, 147
continent urinary diversions, 119, 121–122, see also orthotopic neobladders
contraindications, 111
cutaneous, 244–257
complications, 255–256
techniques, 247–253
ileal conduits vs, 261
quality of life, 386–387
gender, 388
renal function, 117
robot-assisted radical cystectomy, 159
continuous flow resectoscope, 52, 55f
central lymph node metastases, 177
copy number alterations, genes, 330–335
corticosteroids, BCG infection, 83
cost effectiveness, navigator programs, 372
costs
bundled payment initiatives, 399
on follow-up, 376–377
immediate radical cystectomy on, 94
counseling, preoperative, 132
COXEN approach, gene expression models, 279–281, 309
creatinine, continent cutaneous diversions, 244, 245
creatinine clearance, 117, 245
CREBBP gene mutations, 336
cT4bN0 staging, 194–195
Cueto (Club Urológico Español de Tratamiento Oncológico).
soring, 19–20
connective tissue
continent, 244–257
complications, 255–256
techniques, 247–253
metachronous urethral carcinoma, 187
pyelonephritis, 264
urethral dissection, 150
cutaneous ureterostomy, 260
pyelonephritis, 264
cutting loops, 54
Cxbladder (mRNA-based assay), 31
cyclins, genes, 335
cyclophosphamide see CISCA chemotherapy
cycloserine, 83
cylinder, volume, 246
cystectomy, see also partial cystectomy; radical cystectomy; salvage cystectomy
age, 387
BCG therapy and, 79
on fear of recurrence, 380
quality of life, 386
surgical consolidation, 191–193, 194, 196
cystitis
BCG therapy, 79–80, 83
optical coherence tomography, 47
papillary, 7
cystitis cystica, nested variant of urothelial carcinoma vs, 12–14
cystitis glandularis, nested variant of urothelial carcinoma vs, 12–14
cystoscopy, see also photodynamic diagnosis cystoscopy
carcinoma in situ, 21, 41
after chemoradiation, 222
discomfort, 377
follow-up
guidelines, 375–376
HGT1 bladder cancer, 91
partial cystectomy, 218
new modalities, 39–50
for transurethral resection, 51–52
after TURBT, 42
cytokeratin 20, 3
cytokines, response to BCG, 77, 80–82
cytology
follow-up, 376
HGT1 bladder cancer, 91
ileal neobladder, 152–153
ImmunoCyt (biomarker), 28
performance, 26
for urethral carcinoma, 187
UroVysion (biomarker) with, 29
cytomegalovirus (CMV), 336
cytotoxic T-lymphocyte antigen 4 pathway, 358–359
DAPK, gene methylation, 30
deletions, genes, 330
Denovilliers’ fascia, at radical cystectomy, 137, 138f, 139f
depression, 379
detrusor muscle, female urethra, 147
dexterity, of patients, 146
diameter
bowel segment, 246
stoma appliances, 259
dieticians, consultation, 121
differentiated subtype, 345
dilution, intravesical chemotherapy, 68
dilutional hyponatremia (TUR syndrome), 54, 56t
direct invasion, from outside bladder, 11
discharge from hospital, radical cystectomy, 132
disease-free interval
BCG then EMDA-MMC, 71
after second course of BCG, 99–100
disease-specific literacy, 378–379, 382
disparities in healthcare, 365–374
distension of pouches, 246
distrust, 370
divergent differentiation, carcinomas with, 8–9
diverticula (colonic), 245
diverticular tumors (bladder)
partial cystectomy, 213, 214f
transurethral resection, 56–58
DNA alkylators, 65
DNA repair enzymes, 274–275
docetaxel
BCG-refractory urothelial carcinoma, 70, 102–103
combination chemotherapy, 305, 311t
gemcitabine with, 308
second-line chemotherapy, 310
toxicity, 70
dose-dense chemotherapy, 307
double T-pouch, 247, 248f
dovitinib, 311t, 315, 355
doxorubicin, see also AG chemotherapy; CISCA chemotherapy;
MVAC chemotherapy
peplomycin with, 69
drug efflux proteins, 275–276
ductal adenocarcinoma, prostate, 7
Duet automatic scanning system, 29
dysplasia, urothelium, 5f, 6
everal radical cystectomy, 21, 22, 23–24
Eastern Cooperative Oncology Group Performance Status, 114
EAU see European Association of Urology
E-cadherin
blockade, 348
gene methylation, 30
ECOG Performance Status, 114
economic impact
of follow-up, 376–377
on outcomes, 377
educational classes, preoperative, 132
educational levels
bladder carcinoma incidence, 370
health literacy, 378
educational tools, 404
electrolytes, see also metabolic acidosis
jejunal conduits, 261
non-continent urinary diversions, 263
electromotive drug administration, 68, 70–71, 93
electronic health records, 381
embryonic stem cells, 343
cemmprin, gene, 278
EMT (epithelial-to-mesenchymal transition), 348–349
endopelvic fascia, at radical cystectomy, 137
diagnosis see cystoscopy
enhanced recovery programs, 123
ERAS-enhanced recovery, 131–132, 141
EORTC (European Organization for Research and Treatment of Cancer)

diagnosis see cystoscopy
extension, robot-assisted radical cystectomy, 158, 159, 161t, 162t, 163
extraabdominal approach, partial cystectomy, 215
extracapsular extension, lymph node metastases, 178
extracorporeal urinary reconstruction, robot-assisted radical cystectomy, 158, 159, 161t, 162t, 163
extraperitoneal approach, partial cystectomy, 215
extraperitoneal perforation, 56t
extravesical cancer, invasion from, 11
extrophy, adenocarcinoma, 11
facilitators, to follow-up cystoscopy, 379–380
family history, patients' knowledge, 379
fasting
intravesical chemotherapy, 93
radical cystectomy, 131
fast-track recovery programs, 123
FDA (Food and Drug Administration), biomarkers
approved by, 27–33
fear of recurrence, 380
feasibility, healthcare quality measures, 398
federal funding, 405–406
fee-for-service model, modifications, 397–398
female patients, see also gender
orthotopic neobladder surgery, 145–148, 237
follow-up, 151–153
incontinence, 146, 147, 151–152, 153
urinary retention, 240
radical cystectomy, 144–155
posterior dissection, 139–140
urethral carcinoma, 186, 236
urethrectomy, 186

Female Sexual Function Index, 148
fever, BCG therapy, 79, 82, 83
FGFR3 gene, 337, 338f
fusion with TACC3 gene, 336–337
mutations, 30–31, 315, 330, 354–355
fibroblast growth factor receptors, 354–355
fine-needle aspiration, prostate, 185
Finnbladder IV study, 69
fistula
pazopanib, 313
pouch-vaginal, 240
5-azacitidine (AzaC), 357–358
five-year survival
adjunctive (AzaC), 299
advanced carcinoma, 296
BCG failure, 102
BCG therapy, 69, 78, 79, 92
bladder-sparing therapy, 228
diverticular tumors, 57
extended lymphadenectomy, 133, 180, 190
gender, 144
healthcare disparities, 365
hydrenephrosis, 223
immediate vs salvage cystectomy, 227
lymph node metastases, 178, 296
metachronous urethral carcinoma, 187, 188
muscle invasion, 24
neoadjuvant chemotherapy, 118
non-organ-confined bladder carcinoma, 191, 192, 193
radical cystectomy, 140, 141, 162, 168, 284, 285
robot-assisted, 169, 170
repeat transurethral resection, 59
taxanes, 103
thermo-chemotherapy, 68
transurethral resection of bladder cancer, 203
repeat, 59
urachal carcinoma, 214
flat urothelial carcinoma in situ, 5f, 6
flexible cystoscopy, photodynamic diagnosis cystoscopy, 41
fluid management, radical cystectomy, 120
postoperative, 132
fluorescein, for confocal laser endomicroscopy, 45
fluorescence cystoscopy see photodynamic diagnosis cystoscopy
fluorescence in situ hybridization assay, UroVysion
(biomarker), 28–29
fluoroquinolones, BCG infection, 83
fluorouracil
cisplatin chemoradiation with, 225
radiotherapy with, 224–225, 286
renal function, 288
follow-up
conduit urinary diversions, 266
continent cutaneous diversions, 256
HGT1 bladder cancer, 91
muscle-invasive bladder carcinoma, 376
orthotopic neobladders, female patient, 151–153
partial cystectomy, 217–218
psychosocial aspects, 375–383
radical cystectomy, urethra, 187–188
transurethral resection of bladder cancer, 209–210
Food and Drug Administration (US), biomarkers approved by, 27–33
Ford, Betty (First Lady), 402–403
fossa of Maricilles, 129, 136–137
fractionated TURBT, 203
frailty, assessment see functional assessment; poor risk patients
From Cancer Patient to Cancer Survivor (IOM), 377
fulguration, 54, 58
functional assessment, 112–119, see also poor risk patients
funding, for research, 405–406
fusions, gene–gene, 336–337
gastric conduits, 261–262
gastrointestinal complications
orthotopic neobladders, 239
urinary diversions, 386
GATA3 (transcription factor), 347
GC chemotherapy
adjuvant, 300
bevacizumab with, 311t, 312–313
dose-dense, 307
gefitinib with, 315
metastases, 305, 306, 311t
neoadjuvant, 289, 290
poor risk patients, 320, 323
gefitinib, 311t, 314–315, 355, 356t
gemcitabine, 65, see also AG chemotherapy; GC chemotherapy;
PCG chemotherapy
in adjuvant chemotherapy, 66, 300, 301
BCG-refractory urothelial carcinoma, 70, 101–102
mitomycin-C vs, 102
bevacizumab with, 312–313
cisplatin chemoradiation with, 225
metastases, 304
myelotoxicity, 324
in neoadjuvant chemotherapy, 288–289, 290
for recurrent carcinoma, 23
in sequential chemotherapy, 69
taxanes with, 308
gender, see also female patients
on compliance, 377
healthcare disparities, 369
quality of life, 387–388
gene expression analysis, 278–281, 309, 322, 337, 338f, 345
gene therapy see siRNA gene therapy
genitofemoral nerve, at radical cystectomy, 136
Genitourinary Steering Committee, National Cancer Institute, 406
genome-wide association studies, 277
genomics
biomarkers, 33, 301
muscle-invasive bladder carcinoma, 329–341
germline pharmacogenomics, 276–278
GIA stapling device, 237
glandular differentiation, survival benefit, 287
glomerular filtration rate
continent cutaneous diversions, 244, 245
neoadjuvant chemotherapy and, 288
orthotopic neobladders, 236
study of urinary diversions, 265
glycine, toxicity, 56t
glycoprotein A1TA (biomarker), 33
Goodwin’s principle, ureter folding, 145
grading, 3, see also staging
  papillary lesions, 6
  grip strength, 116
GSTM1 (biomarker), 91
GSTT1 (biomarker), 91
HA-HAase test, 31
HAI-1 (biomarker), 33
HAL (hexaminolevulinate), 41–42, 71
Harlem Breast Cancer Navigation Program, 365, 366
Hautmann pouch, 238, 239f
healthcare, see also barriers to healthcare
  disparities, 365–374
  health education, 382
  health literacy, 378–379, 382
  health records, electronic, 381
  health-related quality of life see quality of life
  heat shock proteins, as biomarkers, 33
hematopoietic stem cells, 343
hematuria
  BCG therapy, 79
  after cystoscopy, 377
  misdiagnosis in women, 369
hemodynamic management, radical cystectomy, 120
heparin, 132
hepatocyte growth factor–Met pathway, 356, 357f
Her-2 protein, 355–356
hernias
  incisional, 240–241
  parastomal, 265
hexaminolevulinate (HAL), 41–42, 71
Hexvix (HAL), 41–42, 71
HGT1 bladder cancer, 89–97
  follow-up, 91
  treatment, 91–94
  high-dose MVAC, 307
high-grade papillary urothelial carcinoma, 8
  high-grade T1 urothelial carcinoma see HGT1 bladder cancer
  high-grade Ta urothelial carcinoma, risk stratification, 20–21
histone deacetylase, 316, 357
histones, proteins acting on, 335
historical aspects
  BCG, 77
  intravesical chemotherapy, 64–65
  transurethral resection, 51–52, 55f
history (case) see treatment history
HMOX 1 (biomarker), 91
holmium:YAG laser, 58
hospital care see length of stay
HRAS gene mutations, 333
HSP (heat shock proteins), as biomarkers, 33
hTERT (human telomerase reverse transcriptase), 30, 32
human complement factor H-related protein, 27–28
human papillomavirus 16 (HPV16), 336
human telomerase reverse transcriptase (hTERT), 30, 32
hyaluronic acid
  as biomarker, 31
  paclitaxel with, 103
hyaluronidase (biomarker), 31
hydration see fluid management
hydrogel, intravesical chemotherapy, 68
hydronephrosis
  non-continent urinary diversions, 264
  on survival, 223
  after transurethral resection, 56
hypercontinence, orthotopic neobladders, 152, 240
hypermethylation, promoter regions, 357
hyperplasia, urothelium, 5
hypersensitivity, BCG therapy, 80–82, see also BCG-intolerant urothelial carcinoma
hyperthermia see thermo-chemotherapy
hypertonic saline, 56t
hypocalcemia, 263
hypogastric artery, 128, 129
hypogastric plexus, continence and, 147
hypokalemia, 263
hypomagnesemia, 263
hyponatremia
  dilutional (TUR syndrome), 54, 56t
  jejunal conduits, 261
hypotension, 5-aminolevulinic acid, 105
hysterectomy, 237
ifosfamide see ITP chemotherapy
Iglesias resectoscope, 52, 55f
ileal conduits, 260–261, see also continent urinary diversions
  quality of life, 245, 386
  reflux, 265
  robot-assisted radical cystectomy, 159, 160
  stenosis, 265
ileal end stoma, 262
ileal pouches, orthotopic, 128, 152–153, 237–238
ileocecal segment, conduits, 262, 263
ileocecal valve, 246–247
  imbricated, 246, 252
ileum, contractions, 256
ileus, postoperative, 119–120, see also bowel function return imaging
  colon, 245
  follow-up, 266, 376
preoperative preparation, 112
visceral metastases, 129–130
imbricated ileocecal valve, 246, 252
immediate postoperative intravesical chemotherapy, 66–68
immediate radical cystectomy, 23, 227
HGT1 bladder cancer, 94
immune infiltration, chemosensitivity, 346
immune modulators, 358–359
immune response, BCG, 77, 78f
ImmunoCyt (biomarker), 27t, 28
immunohistochemistry
dysplasia, 6
urothelium, 3
immunosuppression, BCG therapy and, 82
immunotherapy see intravesical immunotherapy
impairment-free survival, radical cystectomy, 114–115
implantation, ureters, 253–255
importance levels, healthcare quality measures, 398
incidence
urethral carcinoma, 185–186, 236
urothelial carcinoma, 127, 144
educational levels, 370
incision
peritoneum, anterior pelvic exenteration, 149
radical cystectomy, 134
peritoneum, 135, 138f
incisional hernia, 240–241
incontinence
bladder-sparing therapy, 227
orthotopic neobladders, 239–240
female patient, 146, 147, 151–152, 153
quality of life, 387
robot-assisted radical cystectomy, 163
incontinent urinary diversions see non-continent urinary diversions
incremental cost effectiveness, navigator programs, 372
Indiana pouch, 246, 249–252
induced pluripotent stem cells (iPS), 343
induction, BCG therapy, 77–78
infections, see also urinary tract infections
orthotopic neobladders, 153, 239, 241
inferior hemorrhoidal artery, 128
inflammation, 4
carcinomas with divergent differentiation, 10
optical coherence tomography, 47
inflammatory pseudotumor, sarcomatoid carcinoma vs, 14
infliximab, BCG therapy and, 82–83
infundibulopelvic ligament, at radical cystectomy, 136
INK4 proteins, 335
innervation, 128–129
inpatient care pathways, 122–123, 131–132, 192
Institute of Medicine
Cancer Care for the Whole Patient, 380
From Cancer Patient to Cancer Survivor, 377
A National Cancer Clinical Trials System for the 21st Century, 406
instrumental interventions, patient navigation, 368
insurance, see also third party payers
on bladder carcinoma outcomes, 370
interferon-alpha
BCG-refractory urothelial carcinoma, 100, 104
BCG therapy with, 23, 83–84
interferon-gamma, BCG therapy, 77
interleukin(s), as biomarkers, 33
interleukin 2, immunotherapy, 84
interleukin 8, pazopanib study, 313
interleukin 10 blockers, 84
interleukin 12, immunotherapy, 84
intermediate subtype, 345
intermittent self-catheterization see catheterization
internal iliac artery, 128, 137
internal pudendal nerve, 128
Internet, 404
intracorporeal urinary reconstruction, see also orthotopic neobladders
robot-assisted radical cystectomy, 159, 161t, 162t, 172
continence, 163
intraperitoneal approach, partial cystectomy, 215
intravenous chemotherapy, molecular targeted agents, 65–66
intravesical chemotherapy, 64–75, see also adjuvant chemotherapy; BCG therapy
BCG-refractory urothelial carcinoma, 101–106
complications, 70
HGT1 bladder cancer, 92–93
improvement methods, 68–69
perforation and, 56
photodynamic diagnosis cystoscopy after, 42
intravesical immunotherapy, 76–88
Ta urothelial carcinoma, 20–21
intrinsic subtypes, 345–347
intussuscepted nipple valve see Kock nipple valve
inverted growth, papillary lesions, 7
inverted papilloma, nested variant of urothelial carcinoma vs, 14
ipilimumab, 359
irrigation, at transurethral resection, 54
ischemic heart disease, 117
isoniazid, 83
ITP chemotherapy, 306–307
jejunals conduits, 261
Karnoñski Performance Score, 114, 321
karyopherin-α2, 91
KDM6A gene mutations, 335
ketorolac, 132
Ki67, as prognostic factor, 322
Kock nipple valve, 246, 249, 251f
obstruction, 241
Kock pouch, 247
stones, 237
KRT14 expression, 345

label-retaining cells (nucleoside uptake), 344
laboratory tests
for radical cystectomy, 112, 114t
visceral metastases, 129–130
lactulose, 132
lamina propria
invasion, 8, 9f
optical coherence tomography, 47
after radiotherapy, 4
substaging of T1 urothelial carcinoma, 90
laparoscopic partial cystectomy, 216–217
laparoscopic radical cystectomy, 156–166, see also robot-assisted radical cystectomy
complication rates, 161
survival rates, 162t
lapatinib, 311t, 356
lasers, at transurethral resection, 58–59
lateral bladder pedicle, radical cystectomy, 137, 138f
leakage, orthotopic neobladders, 239
lean core muscle area, 115
Leapfrog Group, 397
learning curves, robot-assisted radical cystectomy, 157
Le Duc procedure, 253
lenalidomide, 358
length of stay (hospital), 385
robot-assisted radical cystectomy, 159
levofloxacin, BCG infection, 83
Lichtleiter (Bozzini 1804), 51–52
liquid chromatography-tandem mass spectrometry, biomarkers, 33
liquid diet, 132
liver disease
BCG therapy and, 82
radical cystectomy and, 118
local anesthesia, 120
postoperative, 132
loco-regional failure rates, radical cystectomy, 130
longitudinal smooth muscle, female urethra, 146
loop end ileostomy, 262
lower urinary tract symptoms, 89–90
valrubicin, 101
low-grade papillary urothelial carcinoma, 8
luminal subtype, 345, 346
epithelial-to-mesenchymal transition in, 348
transcription factors in, 347
lymphadenectomy (PLND), 128, 129, 130, 133–134, see also extended lymphadenectomy
advanced carcinoma, 196
female patient, 145
partial cystectomy, 215–216
robot-assisted radical cystectomy, 161–162, 169–171
technique, 135–137
lymphatic drainage, 177
lymph node density, 180–181
lymph node of Cloquet, 136
lymph nodes, 129
BCG therapy and, 79
examination, 112
metastases, 129, 177–178, 195–196
five-year survival, 178, 296
predictive GEM, 281
retroperitoneal, 191, 192
number removed, 133, 161, 170, 178, 179–180, 287
pre-sacral, 129, 145
lymphocyte-activated killer cells, 84
lymphoepithelioma-like carcinoma, 14
macrophages, BCG therapy, 77
magnetic resonance imaging
bone metastases, 130
follow-up, 376
maintenance, BCG therapy, 77, 79, 81t
HGT1 bladder cancer, 92
Mainz pouch I, 248–249, 250f, 251f
Mainz pouch III, 253, 254f
malabsorption syndromes, 246
malnutrition, 116
Mansoura (Egypt), radical cystectomy outcomes, 140
manual dexterity, of patients, 146
margins see positive surgical margins
Mcm5, with NMP22 (biomarker), 33
MCV chemotherapy, 226
MD Anderson approach, neoadjuvant chemotherapy, 118–119
MDM2 gene, 335
MDR1 (multidrug resistance gene 1), 275–276
measure group reporting, 397–398
median sacral veins, at radical cystectomy, 136
median umbilical ligament, urachal carcinoma, 12
medical records, electronic, 381
Medicare patients
follow-up, 376–377
undersupply of care, 395–397
megapouches, 246
menopause, on cancer risk, 145
mesentery, at radical cystectomy, 135
meshes, hernia prevention, 265
mesodermal mixed tumor, malignant, 14
messenger RNA, assays, 29t, 31–32
metabolic acidosis, 153, 256
jejunal conduits, 261
metachronous metastases, 193
metachronous urethral carcinoma, 185
detection, 187–188
female patient, 186
urinary diversion type, 187
metaplasia, 343
adenocarcinoma, 11
nephrogenic adenoma, 11
after radiotherapy, 4
metaplastic carcinoma, 14
metastases, see also under lymph nodes
to bladder, 11
chemotherapy, 191–192, 296, 304–306
epithelial-to-mesenchymal transition, 348
metachronous, 193
outcomes of radical cystectomy, 140
radical cystectomy in presence of, 112, 190–197
treatment, 304–319
visceral, 129–130, 321
methotrexate see MCV chemotherapy; MVAC chemotherapy
methotrexate/carboplatin/vinblastine chemotherapy, 322
methylation, analysis for biomarkers, 30
MET signaling, 356, 357f
Michigan Urological Surgery Improvement Collaborative, 399
micropapillary carcinoma, 14
molecular biology, see also biomarkers
chemotherapy, 273–283, 290, 301
molecular targeted agents, 65–66
monoclonal antibodies
cancer stem cell staining, 344
therapy, 315–316
morphometric measures, 115
mortality, 384, 395
African Americans, 368–369
bladder-sparing therapy and, 223
healthcare disparities, 368
partial cystectomy, 217
radical cystectomy, 140, 141, 212
robot-assisted, 160
underinsurance, 370
women, 369
MRE11 (biomarker), 229
mRNA, gene expression analysis, 337, 338f, 345
mRNA-based assays, 29t, 31–32
mTOR pathway, 316, 333–335
müllerian rests, 11
multidisciplinary team approach, 380
multidrug resistance gene 1 (MDR1), 275–276
multimodality bladder-sparing therapy, 218, see also trimodality bladder-sparing therapy
quality of life, 385
multipotent stem cells, 343
multi-targeted agents, 353–361
muscle-invasive bladder carcinoma, 8
after bladder-sparing therapy, 226–227
cisplatin-based chemotherapy, 191
de novo, BCG-refractory, 101
follow-up, 376
genomics, 329–341
neoadjuvant chemotherapy, 284–294
partial cystectomy, 212–220
pathology, 8, 9f
recurrence on risk, 94
muscle wasting, measurement, 115
muscularis mucosae
invasion, 8, 9f
substaging of T1 urothelial carcinoma, 90
muscularis propria
invasion, 8
optical coherence tomography, 47
in tumor resections, 59
HGT1 bladder cancer, 90
mutations, 301, 330–335, see also specific genes
MutSig 1.5, 330
MVAC chemotherapy
  adjuvant, 300
  dose-dense, 307
  metastases, 304–306
  neoadjuvant, 225–226, 286, 287, 289–290
  poor risk patients, 320–321
myelotoxicity, 324
myotomies, ileal end stoma, 262
nanoparticle albumin-bound paclitaxel (nab-paclitaxel), 103, 312
narcotics, 119–120, 131, 132
narrow band imaging, 40f, 42, 43–44, 48
nasogastric decompression, 131
National Cancer Clinical Trials System for the 21st Century, A (IOM), 406
National Cancer Institute
  Bladder Cancer Task Force, 406
  research patient advocates, 406
National Comprehensive Cancer Network (NCCN), 194
  on chemotherapy, 296
  on follow-up, 375, 376
National Institutes of Health, on research, 405
National Patient Navigation Leadership Summit, American Cancer Society, 371
National Quality Forum, 398
navigator programs see patient navigation
NCI-60 cell panel, COXEN approach, 279
NCOR1 gene mutations, 336
needle biopsy, prostate, 185
neoadjuvant chemotherapy, 130
  to bladder-sparing therapy, 225–226
  BRCA1 and, 309
  COXEN approach, 279–281
  muscle-invasive bladder carcinoma, 284–294
  partial cystectomy after, 213
  radical cystectomy, 118–119
  advanced carcinoma, 191
  robot-assisted, 158
  resistance, 274–276
  sensitivity by tumor subtype, 345–346
  surgery delay, 296–299
  transurethral resection of bladder cancer, 59, 209
  vitamin B12 screening, 266
neobladders see orthotopic neobladders
neodymium:YAG laser, 58–59
neostigmine, 132
nephrogenic adenoma, 7, 11
  nested variant of urothelial carcinoma vs, 12–14
nerve sparing, 129, 134, 137
  female patient, 147–148, 149, 150
nerve supply, 128–129
  nested variant of urothelial carcinoma, 12–14
neuroanatomy, 128–129
neuroendocrine carcinoma, 12
Neurofibromatosis 2, gene mutation, 316
NFE2L2 gene mutations, 336
NID2, gene methylation, 30
night sweats, BCG therapy, 83
night time catheterization, on sleep, 386
night time incontinence, 151–152, 240, 387
nipple stoma, 262
nipple valve see Kock nipple valve
Nitze cystoscope, 52, 53f
NMP22 (biomarker), 27t, 28
  Mcm5 with, 33
node of Rosenmüller, 136
nomograms, prognosis, 321
non-bladder cancer, invasion from, 11
non-continent urinary diversions, 258–269
  complications, 263–265
  quality of life, 245, 385, 386, 389t
non-muscle-invasive bladder cancer
  chemoradiation, 228–229
  progression, 64
  quality of life studies, 386, 388
  radical cystectomy, 21, 22, 23–24, 130, 131
  risk stratification, 18–25
non-organ-confined bladder carcinoma, radical cystectomy
  190–197
norepinephrine, radical cystectomy, 120
NRAS gene mutations, 333
nuclear matrix protein 22 see NMP22 (biomarker)
nucleosides, 343–344
nurses
  postoperative care, 123
  stoma care, 121
nutrition, radical cystectomy
  assessment, 116–117
  management, 120–121
  postoperative, 132
obturator fossa, 136
obturator reflex, 54
ofloxacin, 83
omental pedicle graft, radical cystectomy, 140, 150
online communities, 122
operative times, robot-assisted radical cystectomy
  158, 159
opioids, 119–120, 131, 132
Oportuzumab (VB4-845), 105
optical coherence tomography, 40f, 46–47, 48
orosomucoid (biomarker), 33
orthotopic neobladders, 235–243, see also intracorporeal urinary reconstruction
  age, 145–146, 236, 387
  continence, 239–240
  care, 121–122
complications, 238–239
female patient, 151–152, 153, 240
conduit urinary diversions vs. quality of life, 266
female patient, 145–148, 237
complications, 151–152, 153, 240
follow-up, 151–153
urinary retention, 240
ileal, 128, 237–238
metachronous urethral carcinoma, 187
patient selection, 235–236
postoperative care, 132
quality of life, 266, 387
technique, 236–238
ureter implantation, 253
urethral cancer, 151, 187, 236
osmolality, urine, 117
ostomies see stomas
ovaries, removal, 149
overuse of care, 397
oxidative stress, response proteins, gene mutations, 336
p16
gene methylation, 30
as prognostic factor, 322
p21, as prognostic factor, 322
p53, 91, 335
as biomarker for chemosensitivity, 276
for immunohistochemistry, 3
intravesical chemotherapy and, 68
as prognostic factor, 322
transurethral resection of bladder cancer, 207
p53-like cancers, chemotherapy resistance, 337
p53/Rb pathway, 333f, 337
p63 (transcription factor), 347, 348–349
paclitaxel, see also ITP chemotherapy; PCG chemotherapy
Abraxane, 103, 312
BCG-refractory urothelial carcinoma, 102–103
cetuximab with, 316
cisplatin chemoradiation with, 225
gemcitabine with, 308
in neoadjuvant chemotherapy, 289
second-line chemotherapy, 310
trastuzumab with, 315–316
pain
cystoscopy, 377
postoperative, robot-assisted radical cystectomy, 159
pain management, 119–120
perioperative, 132
palliative cystectomy, 112
papillary lesions, 6–7, 8
sessile tumor vs., 207
papillary urothelial hyperplasia, 5
papillary urothelial neoplasm of low malignant potential, 7
papilloma, urothelial, 7
parallel clamp technique, partial cystectomy, 213, 216f
parastomal hernias, 265
partial cystectomy, 212–220
complications, 217
outcomes, 217–218
partnerships, patients with provider teams, 379–380
pathologic tumor stage (pT stage), prognosis, 178
pathology, 3–17
pathways, see also specific pathways
analysis, 337–338
patient advocacy, 402–408
patient navigation, 365–374, 380
evaluation, 371–372
Patient Navigator Outreach and Chronic Disease Prevention Act, 366
patient navigators, 368, 381
patients, micro factors on follow-up, 377–380
patient selection
adjuvant chemotherapy, 296
bladder-sparing therapy, 223–224
continent urinary diversions, 245
orthotopic neobladders, 235–236
partial cystectomy, 213
radical cystectomy, 111–112
radical TURBT, 204–207
patient-to-patient communication, 122
pay-for-performance, 397–398
pazopanib, 311t, 313, 333, 354
PCG chemotherapy, 305
pedicles, radical cystectomy, 137–138
pelvic exenteration see anterior pelvic exenteration
pelvic lymph node dissection see lymphadenectomy
pelvic nerve, 128
pemetrexed, 310
peplomycin, doxorubicin with, 69
perforation
orthotopic neobladders, 241
at transurethral resection, 54, 56, 59, 60
performance-based measures, functional status, 115–116
performance status (PS), chemotherapy choice, 114, 323
periostomal complications, 264
peritoneum
anterior pelvic exenteration, incision, 149
at partial cystectomy, 215
radical cystectomy
division, 136
incision, 135, 138f
perivesical lymph nodes, 129
peroxisome proliferator activator receptor-gamma (PPARγ), 346, 347
personalized neoadjuvant chemotherapy, 290
pH (of urine), 117
intravesical chemotherapy, 68
pharmacogenomics, 276–278
photobleaching, 41
photodynamic diagnosis cystoscopy, 40f, 41–43, 48
carcinoma in situ, 21, 41
confocal laser endomicroscopy with, 46
on survival, 42, 44t
after transurethral resection, 42
at transurethral resection, 58
photodynamic therapy, 71
BCG-refractory urothelial carcinoma, 104–105
recurrence-free survival, 44t, 104
Physician Consortium for Performance Improvement, 398
Physician Quality Reporting System, Centers for Medicare &
Medicaid Services, 397
physiologic assessment, 115–116
physiotherapy, orthotopic neobladders, 240
PI3 kinase/Akt/mTOR pathway, 334f, 338
targeted therapy, 316
PI3 kinase/PTEN/mTOR pathway, 333–335
PIK3CA gene mutation, 301
plasmacytoid carcinoma, 11
platelets, on epithelial-to-mesenchymal transition, 348
platinum see cisplatin-based chemotherapy
pluripotent stem cells, 343
points-based nomograms, prognosis, 321
poised chromatin, 348
polypenkneipe (Grunfeld 1881), 52
poor risk patients, 320–326, see also functional assessment
porphyrins, photodynamic diagnosis cystoscopy, 41
port placement, laparoscopic partial cystectomy, 216–217
positioning
for anterior pelvic exenteration, 149
for radical cystectomy, 134
positive surgical margins
neoadjuvant chemotherapy and, 287
partial cystectomy, avoidance, 215
robot-assisted radical cystectomy, 162, 169, 170t
urethra, 150, 186
positron emission tomography, 130, 194, 195
posterior bladder pedicle, radical cystectomy, 137–138, 140f
posterior dissection (female), radical cystectomy, 139–140
postoperative care
radical cystectomy, 123, 132
stoma care, 121
postoperative ileus, 119–120, see also bowel function return
postoperative pain, robot-assisted radical cystectomy, 159
potassium, deficiency, 263
potency, robot-assisted radical cystectomy, 163
poverty, cancer care access and, 366
PPD (purified protein derivative), BCG therapy results
and, 82, 92, 359
pre-albumin, 117
predictive GEMs, 279–281
prehabilitation, 122
preoperative chemotherapy, 192, 194
neoadjuvant chemotherapy vs, 191
preoperative preparation, 112
continent cutaneous diversions, 245
non-continent urinary diversions, 259–260
partial cystectomy, 215
radical cystectomy, 119–122, 131–132
transurethral resection, 52
pre-sacral lymph nodes, 129, 145
presciatic fossa, 129, 136–137
pressures, intraluminal, bowel segments, 247
pre-surgical chemotherapy see preoperative chemotherapy
previous bladder carcinoma, partial cystectomy and, 213
previous surgery, robot-assisted radical cystectomy, outcome
studies, 158
priming (subcutaneous), BCG therapy, 92, 359
prognosis (term), 324
programmed cell death 1 pathway, 359
progression
BCG failure on, 94, 98, 99, 100
BCG therapy on, 22, 77, 79, 92
carcinoma in situ as risk factor, 21, 99
diverticular tumors, 213
HGT1 bladder cancer, 89
high-risk bladder carcinoma, 18–19, 20
lymphadenectomy on, 181
muscle invasion, 90
non-muscle-invasive bladder cancer, 64
sequential chemotherapy on, 69, 71
TURBT on, 58, 203, 204, 207, 209, 210t
promoter regions, hypermethylation, 357
prostate
cancer research funding, 405–406
ductal adenocarcinoma, 7
radical cystectomy, 138
transurethral resection of, 185–186
urothelial carcinoma, 185, 236
urethral carcinoma after, 187
prostatectomy
orthotopic neobladders after, 236
with radical cystectomy, 188
prostate sparing, 134
prostate-specific antigen, BCG therapy and, 80
prostatic urethra, biopsy, 90, 129
prostatitis, BCG therapy and, 80
prostheses, BCG therapy, 82
proteasome inhibitor therapy, 316
protein-based assays, 29t, 31–33
proteomics, biomarkers, 33
protoporphyrin IX, photodynamic diagnosis cystoscopy, 41
psoas muscle, total area, 115
psychosocial factors
follow-up, 377, 379–380
patient advocacy on, 404
PTEN gene mutations, 333–335
purified protein derivative, BCG therapy results and, 82, 92, 359
pyelonephritis
  cutaneous ureterostomy, 264
uretero-ileal strictures, 255
pyelotransverse-pyelocutaneostomy, 262, 263
pyrazinamide, 83
Quale, DZ and J (founders of BCAN), 403
quality-adjusted life years, immediate radical cystectomy on, 94
quality collaborations, radical cystectomy, 124
quality measures, healthcare, 397–398
quality of care, 395–401
quality of life, 384–394
  bladder-sparing therapy, 227, 386
  continent vs incontinent urinary diversions, 245, 265–266
  measures, 385–386, 388, 389–390
Radachlorin, 71, 104–105
radical cystectomy, 127–143, see also surgical consolidation
  age, 387
  after bladder-sparing therapy, 227
  bladder-sparing therapy vs, 228
  complications, 141, 212
  female patient, 144–155
  posterior dissection, 139–140
HGT1 bladder cancer, 93–94
laparoscopic
  see laparoscopic radical cystectomy
moridity, 212
non-muscle-invasive bladder cancer, 21, 22, 23–24, 130, 131
outcomes, 140–141
  survival, 140–141, 144–145, 162, 168
after partial cystectomy, 218
perioperative management, 111–126, 131–132
robot-assisted
  see robot-assisted radical cystectomy
stage 4 carcinoma, 190–197
for T1 carcinoma, 22
technique, 134–140
urethra, 138, 140, 184–189
  cancer incidence, 185–186, 236
  cancer treatment, 188
  recurrence risk, 150–151
radical prostatectomy, orthotopic neobladders after, 236
radical transurethral resection of bladder cancer, 60, 201–211
radiotherapy
abdominal wall, 216
adjuvant, 193
  partial cystectomy, 218
advanced carcinoma, 194
adverse effects, 385
chemotherapy with, 221–232, 286
fluorouracil with, 224–225, 286
mitomycin-C with, 224–225, 286
before orthotopic neobladder surgery, 236
with partial cystectomy, 218
before radical cystectomy, 118, 129
reactive urothelium after, 4
renal function, 288
survival rates, 228
randomized studies
  extended lymphadenectomy, 181
  robot-assisted radical cystectomy, 172–173
Rapid Assessment of Adult Literacy in Medicine-Short Form, 378
RARbeta, gene methylation, 30
RB1 gene, 335
reactive arthritis, 82
reactive urothelium, 4–5
’readers’, chromatin regulation, 335
reading levels, health literacy, 378
readmission
  cost implications, 399
  prediction, 113
  after radical cystectomy, 123, 141, 239
    robot-assisted, 161
  rates, 385
receptor tyrosine kinase inhibitor therapy, 314–315
receptor tyrosine kinases, genomics, 330–333, 334
records (electronic health records), 381
rectosigmoid colon, mobilization, 135
rectum, at radical cystectomy, 137, 138, 139
recurrence
BCG therapy, prevention by, 78–79
after bladder-sparing therapy, 226–227
carcinoma in situ, after BCG therapy, 99
chemotherapy for, 300, 309–316, 322
fear of, 380
on muscle invasion risk, 94
as outcome measure, 69–70
after partial cystectomy, 217–218
partial cystectomy for, 213
radical cystectomy, 140, 141, 150–151, 241
transurethral resection of bladder cancer, 209
in urethra, risk, 150–151
urinary diversion patients, 266
recurrence-free survival
BCG therapy, 69, 79, 80f, 81, 92
chemotherapy enhancement protocols, 68
extended lymphadenectomy, 133, 180
gemcitabine, 70
intravesical chemotherapy, 59, 66, 67t, 69, 102, 103
photodynamic therapy, 44t, 104
radical cystectomy, 140, 141, 168
repeat transurethral resection, 92
thermo-chemotherapy, 70, 93
redox regulators (TXNIP), gene mutations, 336
referral, delays, 369
reflux
   ileal conduits, 265
   orthotopic neobladders, 238f
   prevention, 237, 241
   after transurethral resection, 56
refluxing techniques, ureter implantation, 253–255
regeneration of urothelium, 343
regional anesthesia, 120
regionalization of care, 397
regionally metastatic bladder carcinoma, 191, 192
relapsing fever, BCG therapy, 83
relationship interventions, patient navigation, 368
renal dysfunction, 117, 118
   alpha1-microglobulin, 266
   neoadjuvant chemotherapy and, 288
   non-continent urinary diversions, 265
   orthotopic neobladders, 153, 236
   survival, 322
renal function
   chemotherapy, 288
   continent cutaneous diversions, 244, 245
   continent urinary diversions, 117
   radiotherapy, 288
renal pelvis, transverse colon conduit, 263
repeat BCG therapy, 99–100
repeat transurethral resection, 59–60
HGT1 bladder cancer, 92
Report to the Nation on Cancer in the Poor (American Cancer Society), 366
reprogramming, 343
research, see also clinical trials
   patient advocacy groups partnering, 405–407
research patient advocates, 406–407
resectoscopes, historical aspects, 52, 551
residual carcinoma, after surgical consolidation, 193
residual urine removal, intravesical chemotherapy, 68
resistance to chemotherapy, 274–276
   p53-like cancers, 337
restaging, transurethral resection of bladder cancer, 21, 59, 207
retention (urinary), orthotopic neobladders, 152, 240
retinoid X nuclear receptor alpha (RXRA) gene mutations, 336
retinol-binding protein, 117
retroperitoneal lymph node metastases, 191
   lymph node dissection, 192
reverse Trendelenburg position, 134
rhabdoid sphincteric mechanism, 128
   nerve sparing, 150
rhabdosphincter complex, 147
ribonucleotide reductase subunit M1 (RRM1), 309
rifampin, BCG infection, 83
Ringer’s solution, radical cystectomy, 120
risk stratification, 130, 321, see also poor risk patients
cancer stem cell markers, 345
non-muscle-invasive bladder cancer, 18–25
robot-assisted partial cystectomy, 216
robot-assisted radical cystectomy, 156–166
   age, 387
   outcome studies, 157, 158, 172
   clinical trials, 167–175
   complications, 159–161, 171–172
robot-assisted surgery
   anesthesia, 120
   orthotopic neobladders, staples, 237
Ropivacaine, 132
rosebud stoma, 262
round ligament, at radical cystectomy, 136
rs1820453 SNP, 277–278
RTK/RAS/PI3K pathway, 333f, 338
rule of 30s, 22
RXRA gene mutations, 336
sacral nerve roots, continence and, 147
SAHA (suberoylanilide hydroxamic acid), 311t, 316
salvage cystectomy, 222–223, 226–227
   orthotopic neobladders after, 236
sarcoma, partial cystectomy, 215
sarcomatoid carcinoma, 14
schistosomiasis, adenocarcinoma, 11
scintigraphy
   bone, 130
   renal scarring, 265
screening
   patient navigation on, 372
   vitamin B12, neoadjuvant chemotherapy, 266
second course BCG therapy, 99–100
second-line chemotherapy, 300, 309–316, 322
seeding, see also spillage of tumor
   BCG therapy, 82
self-catheterization see catheterization
self-efficacy, 377
sepsis, BCG therapy and, 82
septic arthritis, BCG therapy, 82
sequential chemotherapy, 69, 307–308
sequential dilatation, urethra, 53
serosal lined flap valve, 246
sessile tumor, papillary lesions vs, 207
Setting Research Priorities (NIH), 405
sexual function, 148f, 385
   bladder-sparing therapy, 227
   orthotopic neobladders, 122
   robot-assisted radical cystectomy, 163
sigmoid colon
   conduits, 262
   technique, 262–263
   pouches made from, 238
   signet ring cell carcinoma, 11
single-dose intravesical chemotherapy, 59, 66–68
single-J stents, ureterostomy, 260
single nucleotide polymorphisms (SNP), chemotherapy response, 277–278
single photon emission computed tomography, lymphatic drainage, 177
siRNA gene therapy, 66
67L-kDa laminin receptor, 344
Skene glands, 146
skin, stoma complications, 264
Skinner maneuver, 136
skip metastases, lymph nodes, 129, 177
sleep, night time catheterization on, 386
slow-twitch fibers, female urethra, 147
small cell carcinoma, 12
smartphone ownership, 381–382
smooth muscle, female urethra, 146–147
snares (cutting loops), 54
sodium bicarbonate, before intravesical chemotherapy, 68
soft tissue margins see positive surgical margins
somatic mutations, 330–335
sorafenib, 311t, 314, 354
SPARC (Survival Prediction After Radical cystectomy), 113–114
specimens, transurethral resection, 54
HGT1 bladder cancer, 90
spermatic cord, at radical cystectomy, 136
sphincter (urethral), see also rhabdoid sphincteric mechanism
female, 147
innervation, 128
spillage of tumor, see also seeding
partial cystectomy, avoidance, 215, 216f
spinal anesthesia, 120
spindle and giant cell carcinoma, 14
spondyloarthritis, BCG therapy, 82
spouts, stomas, 264
squamous cell carcinoma, 10
squamous cell mucosa, urethra, 150–151
squamous differentiation, survival benefit, 287
STAG2 gene mutations, 336, 337
staging, see also grading
bladder-sparing therapy, 228
for partial cystectomy, 215
TURBT vs cystectomy, 285
urachal carcinoma, 12
urothelial carcinoma, 129–130, 194–195
lymphadenectomy, 178
stakeholders, cancer care, 402
standardization see care pathways
staples
double T-pouch, 248f
Mainz pouch I, 249, 251f
orthotopic neobladder surgery, 237, 241
STAT3 signaling, 346–347
statins, BCG therapy and, 83
stem cells, 342–345
stenosis
ileal conduits, 265
ureterostomy, 260, 264
stents, ureterostomy, 260
Stern–McCarthy resectoscope, 52
steroids, BCG infection, 83
stomach, conduits made from, 261–262
stomas
care, 121
complications, 264
continent cutaneous diversions, 245–246
non-continent urinary diversions, 259, 262–263
preoperative preparation, 132
quality of life, 386
stone formation, 241
on staples, 237
stress incontinence, 146, 147
stress tests, cardiovascular, 118
stress ulcers, prophylaxis, 132
striated urethral sphincter, 147
strictures
orthotopic neobladders, 240, 241
uretero-enteric anastomoses, 255, 264–265
robot-assisted radical cystectomy, 159–160
uretero-ileal, 241, 255, 264
stromal reaction, 9f
Studer ileal pouch, 237
subcutaneous priming, BCG therapy, 92, 359
suberoylanilide hydroxamic acid (SAHA), 311t, 316
submucosal glands, female urethra, 146
submucosal tunneling, appendix, 246, 249, 250f
substaging, T1 urothelial carcinoma, 90–91
subtypes, bladder carcinoma, 345–347, 348
sunitinib, 311t, 314, 354
GC chemotherapy with, 290
superextended lymphadenectomy, 145, 180
superficial bladder cancer, 8
superior vesical artery, at partial cystectomy, 215
support groups, 122, 404
suramin, 66
surgery, history of, 118
Surgical Care and Outcomes Assessment Program, 399
surgical consolidation, 191–193, 194, 196
survival, see also five-year survival; recurrence-free survival
bladder-sparing therapy, 228
cell differentiation and, 287
metachronous urethral carcinoma, 187
photodynamic diagnosis cystoscopy on, 42, 44t
radical cystectomy outcomes, 140–141, 144–145, 162, 168
gender, 144–145
laparoscopic/robotic, 162
radical TURBT, 203, 204, 205f, 206f
renal dysfunction, 322
Survival Prediction After Radical Cystectomy (SPARC), 113–114
survivin
- as biomarker, 32, 322
- gene, 278
- siRNA gene therapy vs, 66
survivorship, 388–390
survivorship care plans, 380, 390
sutures
- double T-pouch, 247
- Mainz pouch I, 249
- Mainz pouch III, 253
SWI/SNF complex, 333f
SWOG schedule, BCG therapy, 76, 79
synchronous carcinoma, urethra, 185
synergism, chemoradiation, 224–225
T1 urothelial carcinoma
- BCG-refractory, treatment, 105f
- BCG therapy, 22
  - failure, 100
- high-grade see HGT1 bladder cancer
- photodynamic diagnosis cystoscopy, 41
- risk stratification, 22
- substaging, 90–91
T4b staging, 194–195
TACC3 gene, fusion with FGFR3 gene, 336–337
tachycardia, 5-aminolevulinic acid, 105
Ta urothelial carcinoma
- BCG-refractory, treatment, 105f
- high-grade, risk stratification, 20–21
- photodynamic diagnosis cystoscopy, 41
taxanes, 65, see also docetaxel; paclitaxel
  - second-line chemotherapy, 310
team approach, 380
telomerase (biomarker), 32
Ten Key Questions Investigators Can Ask Their Patient Advocate, 406–407
terminal ileum
- continence mechanism, 246
  - double T-pouch, 247
TERT (telomerase reverse transcriptase), 30, 32
Th1 cytokines, BCG therapy, 77
The Cancer Genome Atlas (TCGA), 301, 330, 353
thermo-chemotherapy, 68, 70
- HGT1 bladder cancer, 93
  - for recurrent carcinoma, 23
thiopeta, 65
- adjuvant chemotherapy, 66
- toxicity, 70
third party payers, 395, see also insurance
thrombocytopenia, GC chemotherapy, 306
thromboembolism
- bevacizumab with carboplatin and gemcitabine, 313
  - bevacizumab with GC therapy, 312
  - prophylaxis, 52, 119
  - robot-assisted radical cystectomy, 160
Tice strain, BCG, 92
total psoas muscle area, 115
totipotent stem cells, 343
toxicity
- BCG therapy, 79–83
  - bladder-sparing therapy, rates, 227
  - doxorubicin, 70
  - glycine, 56t
  - mitomycin-C, 70
  - pharmacogenomics, 276
  - thiopeta, 70
  - T-pouch, double, 247, 248f
  - T-pouch modification, 237–238
  - transcription factors, intrinsic subtypes of bladder carcinoma, 346–347
transition cell carcinoma, adenocarcinoma vs, 11
transplant patients, BCG therapy and, 82
transuretero-ureterostomy, 260
transurethral resection of bladder cancer (TURBT), 51–63
  - chemoradiation after, 222
  - efficacy, 58
  - HGT1 bladder cancer, 90, 92
  - incomplete, bladder-sparing therapy, 223
  - intravesical chemotherapy after, 66–68
  - intravesical chemotherapy at, 65
  - partial cystectomy vs, 212
  - photodynamic diagnosis cystoscopy after, 42
  - prognostic value of completeness, 208–209
  - radical, 60, 201–211
  - restaging, 21, 59, 207
T1 urothelial carcinoma, 22
  - technique, 53–56
transurethral resection of prostate, 185–186
transurethral resection of urethral carcinoma, 188
transverse colon
  - conduits, 262, 263f
  - Mainz pouch III, 253, 254f
TRAP assay, 32
trastuzumab, 311t, 315–316, 355, 356t
treatment burden, 385, 387–388
treatment history
  - patients’ knowledge, 379
  - surgery, 118
trimodality bladder-sparing therapy, 221–232
  - quality of life, 385
truncating mutations, chromatin regulatory genes, 335, 336
TSC1 gene mutation, 301, 333
tuberculosis, 77
Tuberous sclerosis 1, gene mutation, 316
tubular dysfunction, renal, 266
tumor necrosis factor-related apoptosis-induced ligand (TRAIL), 77
tunneling, submucosal, appendix, 246, 249, 250f
tunnels, continent cutaneous diversion surgery, 246
Turnbull loop stoma, 262
TUR syndrome, 54, 56t
12+2 gene set, mRNA-based assay, 32
TWIST (transcription factor), 348
TWIST1, gene methylation, 30
TXNIP, gene mutations, 336
tyrosine kinase inhibitors (TKIs) see specific drugs

UBC tests, 32–33
ultrasonography, follow-up, 266, 376
umbilicus
  Mainz pouch I, 249
  stoma, 245
understaging
  bladder-sparing therapy, 228
  risk of, 130
  transurethral resection of bladder cancer, 203, 207, 209
underuse of care, 395–397
unipotent stem cells, 343
United Kingdom, Action on Bladder Cancer, 403–404
United States, Europe vs, bladder-sparing therapy, 222, 225
University of Southern California, radical cystectomy outcomes, 140–141
unresectable bladder carcinoma, radical cystectomy, 190–197
urachal carcinoma, 12, 213–215, 217
ureteral orifices, transurethral resection, 56
uretero-enteric anastomoses, strictures, 255, 264–265
  robot-assisted radical cystectomy, 159–160
uretero-ileal strictures, 241, 255, 264
uretero-intestinal stricture, 264–265
ureterostomy, cutaneous, 260
  pyelonephritis, 264
ureters
  connection to neobladder, 145
  for continent cutaneous diversions, 246
  dissection, 128, 135, 149
  folding, 145
  frozen section, 134, 149–150
  implantation, 253–255
  Mainz pouch I, 249
urethra
  female, 146–147
    carcinoma, 186, 236
    dissection, 150
  orthotopic neobladder surgery, 237
  carcinoma, 151, 187
radical cystectomy, 138, 140, 184–189
  cancer incidence, 185–186, 236
  cancer treatment, 188
  recurrence risk, 150–151
  sequential dilatation, 53
urethral sphincter, see also rhabdoid sphincteric mechanism
  female, 147
  innervation, 128
urethrectomy, 134, 184, 188
  female patient, 186
urethroscopy, follow-up, 153
urinary diversions, 119, see also specific types
  age, 258–259, 387
  care, 121
  continent see continent urinary diversions
  liver disease and, 118
  metachronous urethral carcinoma, 187
  non-continent see non-continent urinary diversions
  quality of life, 386–387
  gender, 388
  orthotopic neobladders vs, 266
  renal function, 117, 265
  robot-assisted radical cystectomy, 159
urinary retention, orthotopic neobladders, 152, 240
urinary tract infections, see also pyelonephritis
  BCG therapy and, 80
  misdiagnosis in women, 369
  non-continent urinary diversions, 263–264
  orthotopic neobladders, 153, 239, 241
  ureterostomy, 260
urination, symptoms after cystoscopy, 377
uRNA (mRNA-based assay), 31
Urological Surgery Quality Collaborative, 399
urologists, follow-up, variability, 376
UroSCOAP, 399
urothelial carcinoma, see also BCG-refractory urothelial carcinoma; T1 urothelial carcinoma; Ta urothelial carcinoma
  invasive, pathology, 8, 9f
  nested variant of, 12–14
urothelium, 3–4, 343
  dysplasia, 5f, 6
  hyperplasia, 5
  optical coherence tomography, 47
  reactive, 4–5
UroVysion (biomarker), 27t, 28–29
usability, healthcare quality measures, 398
uterus, removal, 149
vaccine, targeting Her-2 protein, 301
vagina
  fistula, 240
  operative marking, 149
  orthotopic neobladder surgery, 237
radical cystectomy, 139–140
  resection, 149f, 150
  sexual function, 148
sparing, 134, 139, 150
  partial, 150
valrubicin

BCG-refractory urothelial carcinoma, 101
BCG therapy with, 70
HGT1 bladder cancer, 93
for recurrent carcinoma, 23
vandetanib, 311t, 313, 354
vaporization of tumor, 58
vascular anatomy see blood supply
vascular endothelial growth factor (VEGF), 312
agents targeting, 354, 355
vas deferens
at partial cystectomy, 215
at radical cystectomy, 136
VB4-845 (immunotoxin), 105
venous thromboembolism see thromboembolism
vesicoureteral reflux, after transurethral resection, 56
vinblastine see MCV chemotherapy; MVAC chemotherapy
vinflunine, 309, 310–312, 322, 323
vinorelbine, 65
viruses, integration, 336–337
visceral metastases, 129–130, 321

vitamin B12, 153, 263, 266
volume of cylinder, 246
vorinostat (suberoylanilide hydroxamic acid), 311t, 316

Wallace technique, ureter folding, 145
white light cystoscopy, 40–41
whole-genome sequencing, 277
women see female patients; gender
World Health Organization
grading system, 3
papillary lesions, classification, 6
wound healing, immediate vs salvage cystectomy, 227
‘writers’, chromatin regulation, 335

Yang–Monti mechanism, 246
Young Investigator Awards (BCAN), 406
young persons, immediate radical cystectomy, 94
yo-yo phenomenon, transuretero-ureterostomy, 260

ZEB1 gene, 348
zinc-alpha2-glycoprotein (ZAG), biomarker, 33